Ace Report Cover
ISAKOS 2015: 10 day Rivaroxaban reduces venous thromboembolism 3 months after TKA
Reprints
Cite This
Reprints
Cite This
AceReport Image
Arthroplasty
ISAKOS 2015: 10 day Rivaroxaban reduces venous thromboembolism 3 months after TKA

268 patients (330 knees) undergoing primary TKA were randomized into three groups, receiving either rivaroxaban (10mg) for 7 or 10 days post operation, or low molecular weight heparin (5000IU) for 2 days followed by aspirin 100mg for 5 days. The purpose of the study was to analyze the incidence of venous thromboembolism among groups to determine the safety and efficacy of prophylaxis regimens, over 3 months post-surgery. Results indicated that 10 day rivaroxavan treatment was superior in reducing VTE incidence, than 7 day treatment or heparin and aspiring treatment, without increasing complications.

Unlock the full article

Get unlimited access to OrthoEvidence with a free trial
Start Trial

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or continue reading this full article
Register Now
AskOE
Search
Close Search Window
Welcome Back!
Forgot Password?
Create an Account

Account will be affiliated with


OR
Forgot Password?

OR
Check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see the email, please check your spam or junk folder.

For further assistance, contact our support team.

Cite this Ace Report

OrthoEvidence. ISAKOS 2015: 10 day Rivaroxaban reduces venous thromboembolism 3 months after TKA. ACE Report. 2015;5(6):46. Available from: https://myorthoevidence.com/AceReport/Report/

Copy Citation
Share this Ace Report